Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes
dc.contributor.author | Chang, Alfred E. | en_US |
dc.contributor.author | Arca, Marjorie J. | en_US |
dc.contributor.author | Krauss, John C. | en_US |
dc.contributor.author | Cameron, Mark J. | en_US |
dc.contributor.author | Strome, Scott E. | en_US |
dc.date.accessioned | 2006-09-08T19:56:57Z | |
dc.date.available | 2006-09-08T19:56:57Z | |
dc.date.issued | 1996-06 | en_US |
dc.identifier.citation | Arca, Marjorie J.; Krauss, John C.; Strome, Scott E.; Cameron, Mark J.; Chang, A. E.; (1996). "Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes." Cancer Immunology, Immunotherapy 42(4): 237-245. <http://hdl.handle.net/2027.42/42080> | en_US |
dc.identifier.issn | 0340-7004 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/42080 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8665571&dopt=citation | en_US |
dc.description.abstract | We evaluated the in vivo response to the poorly immunogenic B16-BL6 (BL6) murine melanoma genetically altered to secrete interleukin-2 (IL-2), IL-4, interferon γ (IFNγ) and granulocyte/macrophage-colony-stimulating factor (GM-CSF). Three parameters were evaluated: (1) tumorigenicity, (2) vaccination of naive animals, and (3) assessment of antitumor reactivity of T cells derived from tumor-draining lymph nodes (TDLN). Secretion of IL-2 abrogated the tumorigenicity of BL6, while IFNγ and IL-4 partially reduced tumorigenicity, and GM-CSF had no effect. Protective immunity to wild-type tumor challenge could not be achieved by vaccination with irradiated cytokine-secreting tumors, although IL-2 and IL-4 secretion appeared to retard the growth of the challenge inoculum significantly. An alternative method to evaluate the immunogenicity of the cytokine-secreting tumors was to measure the ability of T cells obtained from TDLN to mediate regression of wild-type tumor in adoptive immunotherapy. Neither IL-2 nor IFNγ secretion resulted in the induction of immune T cells. By contrast, GM-CSF and IL-4 secretion were found to induce immune T cells in the TDLN with GM-CSF being superior to IL-4. The combined secretion of GM-CSF and IL-4 did not lead to enhanced induction of immune T cells. GM-CSF secretion was found to up-regulate B7-1 expression in TDLN, consistent with an increase in the population of antigen-presenting cells. These studies demonstrated that reduced tumorigenicity by cytokine secretion did not correlate with increased immunogenicity. With the cytokines examined, there was limited capability of developing protective immunity against the BL6 tumor. Nevertheless, GM-CSF and IL-4 secretion significantly enhanced T cell immune reactivity to the poorly immunogenic BL6 tumor. | en_US |
dc.format.extent | 195785 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag; Springer-Verlag Berlin Heidelberg | en_US |
dc.subject.other | Gene Therapy | en_US |
dc.subject.other | Vaccine | en_US |
dc.subject.other | Cytokines | en_US |
dc.subject.other | Key Words Melanoma | en_US |
dc.subject.other | Legacy | en_US |
dc.subject.other | Adoptive Immunotherapy | en_US |
dc.title | Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Microbiology and Immunology | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Surgery, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA Fax: 313 936 5830; e-mail aechang@umich.edu, US | en_US |
dc.contributor.affiliationum | Department of Surgery, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA Fax: 313 936 5830; e-mail aechang@umich.edu, US | en_US |
dc.contributor.affiliationum | Department of Surgery, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA Fax: 313 936 5830; e-mail aechang@umich.edu, US | en_US |
dc.contributor.affiliationum | Department of Otolaryngology, University of Michigan, Ann Arbor, Mich., USA, US | en_US |
dc.contributor.affiliationother | The Cleveland Clinic Foundation, Cleveland, Ohio, USA, US | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 8665571 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/42080/1/262-42-4-237_60420237.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s002620050276 | en_US |
dc.identifier.source | Cancer Immunology, Immunotherapy | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.